Peter Alping

ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 10

Top Venues

Annals of neurology

Basic & clinical pharmacology & toxicology

Multiple sclerosis (Houndmills, Basingstoke, England)

Neurology

Karolinska Institutet

Karolinska Institutet (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Karolinska Institutet Jun 14 2016

Sweden

PhD Student :: Department of Clinical Neuroscience

Education History

Karolinska Institutet Aug 01 2011 - Jan 13 2017

Sweden

MSC :: Medical Study Programme

Publications

Peter Alping, Martin Neovius, Fredrik Piehl, Thomas Frisell
Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study. Annals of neurology (2024)
Peter Alping, Martin Neovius, Fredrik Piehl, Thomas Frisell
Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study. Annals of neurology 95 (6) (2024)
Fredrik Piehl, Peter Alping, Suvi Virtanen, Simon Englund, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette M Langer-Gould, Jan Lycke, Johan Mellergård, Petra Nilsson, Tomas Olsson, Jonatan Salzer, Anders Svenningsson, Thomas Frisell
COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab. Annals of neurology (2024)
Yihan Hu, Thomas Frisell, Peter Alping, Huan Song, Yudi Pawitan, Fang Fang, Fredrik Piehl
Hospital-Treated Infections and Risk of Disability Worsening in Multiple Sclerosis. Annals of neurology (2024)
Katharina Fink, Agnes Gorczyca, Peter Alping, Simon Englund, Susan Farmand, Annette M Langer-Gould, Fredrik Piehl, Kyla McKay, Thomas Frisell, Neda Razaz
Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study. Multiple sclerosis (Houndmills, Basingstoke, England) (2023)
Peter Alping
Disease-Modifying Therapies in Multiple Sclerosis: A Focused Review of Rituximab. Basic & clinical pharmacology & toxicology (2023)
Peter Alping, Joachim Burman, Jan Lycke, Thomas Frisell, Fredrik Piehl
Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. Neurology 96 (11) (2021)
Peter Alping, Johan Askling, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Magnus Vrethem, Tomas Olsson, Fredrik Piehl, Thomas Frisell
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Annals of neurology 87 (5) (2020)
Peter Alping, Thomas Frisell, Lenka Novakova, Protik Islam-Jakobsson, Jonatan Salzer, Anna Björck, Markus Axelsson, Clas Malmeström, Katharina Fink, Jan Lycke, Anders Svenningsson, Fredrik Piehl
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of neurology 79 (6) (2016)
Peter Alping, Thomas Frisell, Anders Svenningsson, Fredrik Piehl
Reply. Annals of neurology 80 (5) (2016)

Peter Alping.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Peter Alping